• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Reviews in Urology >PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy
【24h】

PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy

机译：PDE-5抑制剂治疗保留神经的根治性耻骨后前列腺切除术继发的勃起功能障碍

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The majority of patients receiving therapy for erectile dysfunction (ED) following post-radical retropubic prostatectomy (RRP) are treated with phosphodiesterase (PDE)-5 inhibitors, which seem to have variable efficacy in this population. So far, the only head-to-head trials with PDE-5 inhibitors have been in general ED patients and not in post-RRP patients. Both vardenafil and tadalafil failed to meet statistical noninferiority to sildenafil in head-to-head trials. To date, only sildenafil has demonstrated efficacy in the prevention of post-nerve-sparing RRP ED. The selection of a PDE-5 inhibitor requires consideration of the patient’s sexual activity pattern as well as the drug’s efficacy and its ability to meet the patient’s expectations. In this regard, sildenafil continues to account for almost 70% of PDE-5 inhibitor prescriptions in the United States.
机译：根治性耻骨后前列腺切除术（RRP）后接受勃起功能障碍（ED）治疗的大多数患者都接受了磷酸二酯酶（PDE）-5抑制剂的治疗，该药物在该人群中似乎具有可变的疗效。到目前为止，只有PED-5抑制剂的头对头试验是针对普通ED患者，而非针对RRP后患者。在头对头试验中，伐地那非和他达拉非均未达到西地那非的统计学非劣效性。迄今为止，只有西地那非已显示出预防神经后保留RRP ED的功效。选择PDE-5抑制剂时，需要考虑患者的性活动方式以及药物的功效及其满足患者期望的能力。在这方面，西地那非在美国继续占PDE-5抑制剂处方的近70％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号